Bicycle Therapeutics plc
BCYC
$7.12
$0.020.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -51.28% | -38.18% | 30.76% | 48.60% | 75.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.28% | -38.18% | 30.76% | 48.60% | 75.74% |
| Cost of Revenue | -30.31% | -48.47% | -63.05% | 26.97% | 38.76% |
| Gross Profit | 26.57% | 55.24% | 85.45% | -22.03% | -29.95% |
| SG&A Expenses | 27.94% | 20.92% | 16.54% | 7.67% | 15.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.95% | 23.76% | 13.01% | 21.06% | 31.62% |
| Operating Income | -57.21% | -38.09% | -10.49% | -16.99% | -24.86% |
| Income Before Tax | -52.26% | -25.41% | 3.02% | -5.48% | -14.97% |
| Income Tax Expenses | -348.11% | -418.96% | -427.04% | -569.04% | 231.46% |
| Earnings from Continuing Operations | -46.56% | -20.85% | 6.44% | -2.93% | -18.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.56% | -20.85% | 6.44% | -2.93% | -18.13% |
| EBIT | -57.21% | -38.09% | -10.49% | -16.99% | -24.86% |
| EBITDA | -59.04% | -39.26% | -10.52% | -17.12% | -25.33% |
| EPS Basic | 7.95% | 29.70% | 43.93% | 34.10% | 18.59% |
| Normalized Basic EPS | 2.88% | 26.11% | 41.23% | 33.33% | 20.86% |
| EPS Diluted | 7.95% | 29.70% | 43.93% | 34.10% | 18.59% |
| Normalized Diluted EPS | 2.88% | 26.11% | 41.23% | 33.33% | 20.86% |
| Average Basic Shares Outstanding | 56.61% | 67.52% | 63.58% | 59.07% | 47.64% |
| Average Diluted Shares Outstanding | 56.61% | 67.52% | 63.58% | 59.07% | 47.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |